Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone-Reference-Cited by-同舟云学术

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone

Published:2019-04-30 Issue:2 Volume:176 Page:377-386
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Sestak Ivana^ORCID,Martín Miguel,Dubsky Peter,Kronenwett Ralf,Rojo Federico,Cuzick Jack,Filipits Martin,Ruiz Amparo,Gradishar William,Soliman Hatem,Schwartzberg Lee,Buus Richard,Hlauschek Dominik,Rodríguez-Lescure Alvaro,Gnant Michael

Funder

Cancer Research UK

Myriad Genetics

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-019-05226-8.pdf

Reference24 articles.

1. Early Breast Cancer Trialists’ Collaborative G, Peto R, Davies C et al 2012 Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432–444

2. Sestak I, Buus R, Cuzick J et al (2018) Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol 4:545–553